Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
_256_384.jpg)
Glenmark released Picture Post Cards on World Vitiligo Day
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Open a printable version of this pageEmail the URL of this page to a friend
Subscribe To Our Newsletter & Stay Updated
